Home
HUMAW
HUMAW News

Latest Humacyte Inc. Warrant (HUMAW) News on October 11, 2025

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

Zacks

4 days ago

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

MT Newswires

4 days ago

Top Midday Decliners

Humacyte Gains 43%, Insider Trades Reap Benefit

Simply Wall St.

4 days ago

Humacyte Gains 43%, Insider Trades Reap Benefit

MT Newswires

4 days ago

Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

GlobeNewswire

4 days ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

Zacks

4 months ago

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),

Simply Wall St.

4 months ago

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

Zacks

4 months ago

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

GlobeNewswire

4 months ago

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

GlobeNewswire

4 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

GlobeNewswire

5 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

GlobeNewswire

5 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Insiders Placed Bullish Bets Worth US$949.4k

Simply Wall St.

5 months ago

Humacyte Insiders Placed Bullish Bets Worth US$949.4k

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

TipRanks

6 months ago

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

Humacyte price target lowered to $8 from $10 at BTIG

TipRanks

6 months ago

Humacyte price target lowered to $8 from $10 at BTIG

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

GlobeNewswire

7 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire

7 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire

7 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

GlobeNewswire

7 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Business Wire

7 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

GlobeNewswire

7 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

7 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

GlobeNewswire

7 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

GlobeNewswire

8 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Simply Wall St.

8 months ago

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

GlobeNewswire

8 months ago

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

GlobeNewswire

9 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

GlobeNewswire

9 months ago

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte price target raised to $17 from $15 at Benchmark

TipRanks

10 months ago

Humacyte price target raised to $17 from $15 at Benchmark

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.

10 months ago

High Growth Tech Stocks to Watch in December 2024

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

GlobeNewswire

10 months ago

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m

Simply Wall St.

10 months ago

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

10 months ago

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

GlobeNewswire

a year ago

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Simply Wall St.

a year ago

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

GlobeNewswire

a year ago

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

GlobeNewswire

a year ago

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

GlobeNewswire

a year ago

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

Humacyte Third Quarter 2024 Financial Results and Business Update

GlobeNewswire

a year ago

Humacyte Third Quarter 2024 Financial Results and Business Update

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

GlobeNewswire

a year ago

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

GlobeNewswire

a year ago

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in October 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

The Wall Street Journal

a year ago

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

GlobeNewswire

a year ago

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

Humacyte Launches $30M Stock and Warrants Offering

TipRanks

a year ago

Humacyte Launches $30M Stock and Warrants Offering

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

GlobeNewswire

a year ago

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

GlobeNewswire

a year ago

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

Humacyte to Participate at Upcoming Investor Conferences in September

GlobeNewswire

a year ago

Humacyte to Participate at Upcoming Investor Conferences in September

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

GlobeNewswire

a year ago

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

Humacyte Second Quarter 2024 Financial Results and Business Update

GlobeNewswire

a year ago

Humacyte Second Quarter 2024 Financial Results and Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

GlobeNewswire

a year ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

GlobeNewswire

a year ago

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

GlobeNewswire

a year ago

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

Business Wire

a year ago

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership

Simply Wall St.

a year ago

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

GlobeNewswire

a year ago

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

GlobeNewswire

a year ago

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

Business Wire

a year ago

Net Asset Value(s)

Dstny honored with 'Employee Wellbeing Award'

PR Newswire

a year ago

Dstny honored with 'Employee Wellbeing Award'

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

PR Newswire

a year ago

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

GlobeNewswire

a year ago

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Business Wire

a year ago

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

GlobeNewswire

a year ago

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Newsfile

a year ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Business Wire

a year ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Journal-News, Hamilton, Ohio

a year ago

Retiring ODW executive to be first inductee in Hamilton Business Hall of Fame

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Motley Fool

a year ago

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

TechCrunch

a year ago

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Bloomberg

a year ago

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate

Simply Wall St.

a year ago

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)

GuruFocus.com

a year ago

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)

Humacyte to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Humacyte to Present at the Jefferies Global Healthcare Conference

This Humacyte Insider Increased Their Holding By 91% Last Year

Simply Wall St.

a year ago

This Humacyte Insider Increased Their Holding By 91% Last Year

Humacyte to Participate at Upcoming Investor Conferences in May

GlobeNewswire

a year ago

Humacyte to Participate at Upcoming Investor Conferences in May

GuruFocus.com

a year ago

Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances

Humacyte First Quarter 2024 Financial Results and Business Update

GlobeNewswire

a year ago

Humacyte First Quarter 2024 Financial Results and Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

GlobeNewswire

a year ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

GlobeNewswire

2 years ago

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

GlobeNewswire

2 years ago

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

GlobeNewswire

2 years ago

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

2 years ago

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

GlobeNewswire

2 years ago

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 years ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

GlobeNewswire

2 years ago

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

Is There Any Hope for Cassava Sciences Stock?

Motley Fool

2 years ago

Is There Any Hope for Cassava Sciences Stock?

Hub Cyber Security Has Sealed Another Agreement With a Leading Credit Card Service Company

GlobeNewswire

2 years ago

Hub Cyber Security Has Sealed Another Agreement With a Leading Credit Card Service Company

Share on Social Networks: